Desmopressin augments pituitary-adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers. — CFSMEATLAS
Desmopressin augments pituitary-adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers.
Scott, L V, Medbak, S, Dinan, T G · Biological psychiatry · 1999 · DOI
Quick Summary
This study tested whether a synthetic hormone called desmopressin could improve how the pituitary gland responds to stress signals in people with ME/CFS. Researchers gave ME/CFS patients and healthy volunteers different hormone combinations and measured their stress hormone responses. When desmopressin was added to another hormone (CRH), it boosted the pituitary gland's response in both groups, but especially in people with ME/CFS.
Why It Matters
This research provides evidence that the blunted stress hormone response observed in many ME/CFS patients may not reflect irreversible pituitary damage, but rather a functional imbalance that can be modulated pharmacologically. The findings suggest a specific neuroendocrine mechanism—altered vasopressin signaling—that could be targeted therapeutically to improve hormonal dysfunction in ME/CFS.
Observed Findings
ACTH response to CRH alone was significantly lower in CFS patients (21.0 ng/L) than controls (57.8 ng/L)
Cortisol response to CRH alone was significantly reduced in CFS (157.6 nmol/L) vs controls (303.5 nmol/L)
Desmopressin (DDAVP) alone produced no significant difference in hormone responses between groups
When DDAVP was combined with CRH, cortisol output increased more in the CFS group than the control group
The combination of CRH and DDAVP normalized pituitary-adrenal responsiveness in CFS subjects
Inferred Conclusions
ME/CFS patients have a blunted pituitary-adrenal response to CRH that can be normalized by adding desmopressin
Desmopressin augments CRH-mediated hormone release in both healthy subjects and CFS patients
CFS may involve increased vasopressinergic sensitivity at the pituitary gland and/or altered adrenal function
The defective stress hormone response in CFS may be functionally reversible rather than due to permanent gland damage
Remaining Questions
Would chronic DDAVP administration improve ME/CFS symptoms or quality of life, or is this only an acute pharmacological effect?
What This Study Does Not Prove
This study does not prove that vasopressin dysfunction causes ME/CFS, only that it may contribute to observed hormonal abnormalities. The acute hormone challenge results do not demonstrate whether DDAVP would be therapeutically effective in treating ME/CFS symptoms in clinical practice. The small sample size and single time-point design limit conclusions about the wider ME/CFS population.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
What mechanisms underlie the increased vasopressinergic responsivity observed in CFS—is it receptor upregulation, altered signaling, or adrenal changes?
How do these neuroendocrine findings relate to the post-exertional malaise and other cardinal symptoms of ME/CFS?
Do these hormonal abnormalities generalize across the broader ME/CFS population, or are they specific to a subgroup?